Effect of Nano-Curcumin On Neoadjuvant Chemotherapy of Bladder Cancer Patients

Evaluating The Effects of Nano-Curcumin On Adverse Effects And Response Of Neoadjuvant Chemotherapy In Bladder Cancer Patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180226038875N1

Enrollment

Registered

2018-10-07

Start date

2016-09-22

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer. Malignant neoplasm of bladder

Interventions

Intervention 1: Intervention group: Nanocurcumin 80 mg capsules manufactured by Exir Nano Sina are taken by patients two times daily for 12 weeks during chemotherapy. Intervention 2: Control group: Pl

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients with TCC of Bladder ECOG performance of 0 or 1 candidate to receive neoadjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Metastatic disease age under 18 or over 80

Design outcomes

Primary

Measure	Time frame
Clinical complete response to chemotherapy. Timepoint: 4 weeks after completion of chemotherapy. Method of measurement: cystoscopy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaleh Sandoughdaran

Shahid Beheshti University of Medical Sciences

sandoughdaran@sbmu.ac.ir+98 21 4442 0082

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026